Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 1/20 | 0.61 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1748405 | 0.82 | CA1 (0.48) | PSIP1APOBEC3GHTR6ALDH1A1HSD17B10 | |
| SCHEMBL778246 | 0.80 | PSIP1 (0.56) | PSIP1APOBEC3GHTR6HSD11B1ALDH1A1 | |
| SCHEMBL777601 | 0.78 | PSIP1 (0.67) | PSIP1HTR6HSD11B1ALDH1A1HSD17B10 | |
| SCHEMBL64761 | 0.78 | PSIP1 (0.67) | PSIP1HTR6HSD11B1ALDH1A1HSD17B10 | |
| SCHEMBL15199478 | 0.77 | MMP2 (0.46) | HSD11B1ALDH1A1HSD17B10CA1CA2 | |
| SCHEMBL1546083 | 0.77 | PSIP1 (0.52) | PSIP1HTR6HSD11B1ALDH1A1CA2 | |
| SCHEMBL180713 | 0.76 | PSIP1 (1.00) | PSIP1HTR6HSD11B1ALDH1A1HSD17B10 | |
| SCHEMBL3329009 | 0.76 | PSIP1 (0.64) | PSIP1HTR6HSD11B1ALDH1A1HSD17B10 | |
| SCHEMBL2646690 | 0.76 | PLCG1 (0.44) | PSIP1HTR6HSD11B1CA12CA1 | |
| SCHEMBL10437234 | 0.75 | CA2 (0.57) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113493386-A | Novel high-selectivity asymmetric synthesis process of 2-fluorocyclopropylamine | 北京桦冠生物技术有限公司 | 2021-10-12 | — | — | CN | claimed |
| EP-0724566-A1 | 1,2-DIARYLCYCLOPENTENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-08-07 | — | — | EP | claimed |
| WO-1995011883-A1 | 1,2-DIARYLCYCLOPENTENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1995-05-04 | — | — | WO | claimed |
| US-20260116912-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260116911-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4717314-A2 | 3,3 DISUBSTITUTED 19-NOR PREGNANE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Sage Therapeutics, LLC (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-3572417-B1 | 3,3 DISUBSTITUTED 19-NOR PREGNANE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4660199-A1 | 19-NOR NEUROACTIVE STEROIDS FOR INDUCING SEDATION | Sage Therapeutics, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| CN-121064178-A | Method for synthesizing ICLEPERTIN | 济南诺博汀精细化工有限公司 | 2025-12-05 | — | — | CN | disclosed |
| EP-4640277-A2 | 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID FOR USE IN THERAPY | Sage Therapeutics, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250319106-A1 | 19-NOR C3, 3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-0365849-B1 | Novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl adenosine derivatives | MERRELL DOW PHARMA (US) | 1994-09-14 | — | — | EP | disclosed |
| WO-1993023370-A1 | PROCESS FOR THE PREPARATION OF FLUOROMETHYL THIO BENZENES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| CN-1022248-C | Novel 2'-halomethylidene, uridine and guanosine drivatives | MERRELL DOW PHARMA (US) | 1993-09-29 | — | — | CN | disclosed |
| EP-0403559-A1 | IMPROVEMENTS RELATING TO ANTIGENS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1990-12-27 | — | — | EP | disclosed |
| CN-1046334-A | New 2 '-halogenated methylene, 2 '-vinylidene and 2 '-the ethynyl adenosine derivative | MERRELL DOW PHARMA (US) | 1990-10-24 | — | — | CN | disclosed |
| CN-1042715-A | New 2 '-halogenated methylene, 2 '-vinylidene and 2 '-ethynyl cytidine, uridine and black glycoside derivates | MERRELL DOW PHARMA (US) | 1990-06-06 | — | — | CN | disclosed |
| EP-0365849-A2 | Novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl adenosine derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-05-02 | — | — | EP | disclosed |
| EP-0336562-A1 | Improvements relating to antigens | CANCER RESEARCH CAMPAIGN TECHNOLOGY LTD. (GB) | 1989-10-11 | — | — | EP | disclosed |
| WO-1989007947-A1 | IMPROVEMENTS RELATING TO ANTIGENS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1989-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319106-A1 | 19-NOR C3, 3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF | NR3C2, NR3C1, CYP11B1 | PSIP1 3270/4885APOBEC3G 3089/4885HTR6 547/4885 |
| US-20260116912-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SCN4A, CHRNA4, CACNG4 | PSIP1 1090/4885APOBEC3G 4344/4885HTR6 267/4885 |
| US-20260116911-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SCN4A, CACNG4, SLC6A4 | PSIP1 1006/4885APOBEC3G 4211/4885HTR6 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.